<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356265</url>
  </required_header>
  <id_info>
    <org_study_id>HUM 00000261</org_study_id>
    <secondary_id>5R33DK071222</secondary_id>
    <nct_id>NCT00356265</nct_id>
  </id_info>
  <brief_title>Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide</brief_title>
  <official_title>Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about why most patients with early stages of
      kidney disease have high blood pressure.

      We know the body produces natural substances that cause blood vessels to open wider to carry
      more blood when needed. An example is during exercise. Other natural substances cause blood
      vessels to get smaller and slow down blood flow when needed. An example is when people are
      cold. The balance between these substances is important. People with kidney disease and high
      blood pressure do not have the normal balance of these substances.

      This study will include 3 groups of people, people with normal blood pressure, people with
      high blood pressure and people with kidney disease.

        -  Subjects will have a screening physical examination, including an ECG and laboratory
           tests

        -  Subjects with high blood pressure may not take their regular blood pressure medication
           for 3 weeks prior to the inpatient GCRC study

        -  Subjects will be given intra-arterial medications that will cause changes in the blood
           vessels during the in-patient study.

      The study will then compare the responses of the three groups. A GFR test will be done to
      confirm the renal function of the group with chronic kidney disease.

      These studies will provide insight into the mechanisms of the pathogenesis of enhanced α1
      vasoreactivity in subjects with progressive renal disease. This will lay the groundwork for
      new strategies in the treatment and prevention of vascular disease among the rapidly growing
      group of individuals with CKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enhanced adrenergic vascular reactivity may significantly contribute to hypertension and the
      excessive cardiovascular disease burden in patients with chronic kidney disease (CKD). Nitric
      oxide (NO), a modulator of neurovascular function, may be linked to adrenergic vascular
      responsiveness. The central HYPOTHESIS is that the reduction in endothelial nitric oxide (NO)
      bioavailability contributes to the enhancement of α1-adrenoceptor vasomotor function in
      patients with CKD.

      Specific Aims: In patients with mild to moderate CKD, compared to matched hypertensive and
      normotensive controls without CKD:

        1. Determine if α1-adrenoceptor vasoreactivity is enhanced less by inhibition of
           endothelial NO

        2. Determine whether α1-adrenoceptor vasoreactivity correlates with plasma levels of the
           endogenous NO inhibitor, asymmetrical dimethylarginine.

      Methods: CKD will be confirmed by I125-iothalamate glomerular filtration rate. Regional
      α1-adrenoceptor vasoreactivity (sensitivity [EC50], reactivity [slope]) will be assessed by
      venous plethsymography using a graded intra-arterial infusion of the α1-adrenoceptor agonist,
      phenylephrine. Comparisons of vasoreactivity at baseline and during infusions of L-NMMA will
      be made between hypertensive non-diabetic subjects with glomerular filtrations rates between
      30-70 ml/min age-, gender-, ethnicity- and % body fat-matched hypertensive and normotensive
      subjects with normal kidney function. In addition, plasma levels of the endogenous NO
      inhibitor, asymmetric dimethylarginine will be measured in the hypertensive subjects with and
      without CKD and compared to vasoreactivity.

      Significance. These studies will provide insight into the mechanisms of the pathogenesis of
      enhanced α1 vasoreactivity in subjects with progressive renal disease.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility: Impossible to recruit enough hypertensive participants to match Chronic Kidney
    Disease (CKD) participants on needed parameters.
  </why_stopped>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All three groups will have the same intervention</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>α1-adrenoceptor Vasoreactivity With L-NMMA</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>Vasoreactivity is defined as Forearm blood flow, dose response curve; ml per minute per log of phenylephrine, or FABF ml/min/logPE;
The x axis is the ml/min value and the y axis is the log Phenylephrine concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α1-adrenoceptor Vasoreactivity With Endogenous ADMA</measure>
    <time_frame>up to 8 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>CKD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertension group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normotensive group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procedure: Regional phenylephrine arterial infusion</intervention_name>
    <arm_group_label>CKD</arm_group_label>
    <arm_group_label>Hypertension group</arm_group_label>
    <arm_group_label>Normotensive group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and Women-18 to 55 years of age.

          -  There are three groups of volunteers.

               -  Group A. People who are hypertensive with kidney disease. When not taking blood
                  pressure medicines, blood pressure must have a systolic between 140-170 mmHg.
                  Diastolic must be between 90-109 mmHg.Kidney function should be around half of
                  normal. Urine protein must be no more than 1 gram in a 24-hour urine time period.

               -  Group B. People who are hypertensive without kidney disease. Blood pressure must
                  have a systolic between 140-170 mmHg. Diastolic must be between 90-109 mmHg.
                  Kidney function should be normal. Normal amounts of protein in their urine.

               -  Group C. People who are normotensive. Blood pressure must have a systolic below
                  131/mmHg. Diastolic must be below 81 mmHg. Kidney function should be normal. No
                  more than normal amounts of protein in their urine.

        Exclusion Criteria:

        People with:

          -  Diabetes

          -  Lung disease

          -  Stomach disease

          -  Liver disease

          -  Blood vessel disease

          -  Heart disease

          -  Hereditary blood disorders

          -  Hematocrit (amount of red blood cells) less than 30%

          -  Current tobacco use

          -  Kidney disease who require dialysis

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Crystal A Gadegbeku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor of Medicine, University of Michigan Health System, Department of Internal Medicine, Division of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2006</study_first_posted>
  <results_first_submitted>November 8, 2017</results_first_submitted>
  <results_first_submitted_qc>December 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Crystal A. Gadegbeku</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Blood Pressure Nitric Oxide</keyword>
  <keyword>L-NMMA</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>Vasoreactivity</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three screen failures</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chronic Kidney Disease (CKD)</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="P2">
          <title>Hypertension Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="P3">
          <title>Normotensive Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chronic Kidney Disease</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="B2">
          <title>Hypertension Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="B3">
          <title>Normotensive Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>α1-adrenoceptor Vasoreactivity With L-NMMA</title>
        <description>Vasoreactivity is defined as Forearm blood flow, dose response curve; ml per minute per log of phenylephrine, or FABF ml/min/logPE;
The x axis is the ml/min value and the y axis is the log Phenylephrine concentration.</description>
        <time_frame>up to 8 hours</time_frame>
        <population>Based on the data from the 12 participants, and the early termination, no analysis was performed on the two hypertensive participants' data.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease</title>
            <description>Procedure: Regional phenylephrine arterial infusion</description>
          </group>
          <group group_id="O2">
            <title>Normotensive Group</title>
          </group>
        </group_list>
        <measure>
          <title>α1-adrenoceptor Vasoreactivity With L-NMMA</title>
          <description>Vasoreactivity is defined as Forearm blood flow, dose response curve; ml per minute per log of phenylephrine, or FABF ml/min/logPE;
The x axis is the ml/min value and the y axis is the log Phenylephrine concentration.</description>
          <population>Based on the data from the 12 participants, and the early termination, no analysis was performed on the two hypertensive participants' data.</population>
          <units>ml/min x 1/log[PE]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>before L-NMMA infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.10"/>
                    <measurement group_id="O2" value="-0.22" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>after L-NMMA infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.09"/>
                    <measurement group_id="O2" value="-0.16" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>α1-adrenoceptor Vasoreactivity With Endogenous ADMA</title>
        <time_frame>up to 8 hours</time_frame>
        <population>The main goal of the study was to compare vasoreactivity across the three groups. Given the fact that we struggled to recruit matched hypertensive and normotensive control population, we were not able to achieve the goals of the study and therefore, ADMA levels were not measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease</title>
            <description>Procedure: Regional phenylephrine arterial infusion</description>
          </group>
          <group group_id="O2">
            <title>Hypertension Group</title>
            <description>Procedure: Regional phenylephrine arterial infusion</description>
          </group>
          <group group_id="O3">
            <title>Normotensive Group</title>
            <description>Procedure: Regional phenylephrine arterial infusion</description>
          </group>
        </group_list>
        <measure>
          <title>α1-adrenoceptor Vasoreactivity With Endogenous ADMA</title>
          <population>The main goal of the study was to compare vasoreactivity across the three groups. Given the fact that we struggled to recruit matched hypertensive and normotensive control population, we were not able to achieve the goals of the study and therefore, ADMA levels were not measured.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were interviewed for safety follow up approximately 7 - 10 days after procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chronic Kidney Disease</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="E2">
          <title>Hypertension Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
        <group group_id="E3">
          <title>Normotensive Group</title>
          <description>Procedure: Regional phenylephrine arterial infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Crystal Gadegbeku</name_or_title>
      <organization>University of Michigan</organization>
      <email>crystal.Gadebeku@tuhs.temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

